/
MNOV
$1.31-$0.01 (-0.76%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$65.0M
49M shares
52-week range
$1.17 – $1.96
18% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.43%
Moderate
Price (6 mo)
Loading chart…
Change$-2.84
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $4.0M | $0 | $1.0M | $0 | $409.7K |
| Cost of revenue | $25.9K | $23.9K | $0 | $0 | $0 | $0 | $0 | $378.6K |
| Gross profit | −$25.9K | −$23.9K | $0 | $4.0M | $0 | $1.0M | $0 | $31.1K |
| Gross margin | — | — | — | 100.0% | — | 100.0% | — | 7.6% |
| R&D | $5.6M | $6.1M | $7.5M | $8.1M | $9.1M | $5.7M | $7.2M | $7.2M |
| Operating income | −$15.6M | −$14.0M | −$14.2M | −$10.2M | −$14.6M | −$9.9M | −$12.7M | −$13.3M |
| EBITDA | −$15.6M | −$14.0M | −$14.2M | −$10.1M | −$14.0M | −$8.5M | −$11.0M | −$12.0M |
| Net income | −$14.7M | −$12.9M | −$13.9M | −$10.1M | −$14.1M | −$8.6M | −$11.0M | −$12.0M |
| Net margin | — | — | — | -251.0% | — | -857.2% | — | -2928.8% |
| EPS (diluted) | -0.36 | -0.30 | -0.31 | -0.21 | -0.29 | -0.17 | -0.23 | -0.24 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $295667 | $-0.26 | $-0.30–$-0.22 | 2 |
| 2027 | $800000 | $-0.38 | $-0.44–$-0.31 | 1 |
| 2028 | $43M | $0.08 | $-0.13–$0.29 | 2 |
| 2029 | $126M | $1.05 | $0.87–$1.23 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.61
Price
$1.31
Implied downside
-53%
Peer comparison
Medicinova, Inc.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
www.medicinova.com- Employees
- 6
- IPO / List date
- Dec 7, 2006
- HQ
- LA JOLLA, CA
Held by traders on TradeandTell
No one on the platform currently holds MNOV.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 189,900 | $260.2K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MNOV yet.
